Nurix Therapeutics (NRIX) Total Current Liabilities (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Total Current Liabilities for 8 consecutive years, with $72.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Total Current Liabilities fell 4.75% year-over-year to $72.0 million; the TTM figure through May 2026 stood at $72.0 million (down 4.75% YoY), while the FY2025 annual figure was $86.5 million, down 9.79% from the prior year.
• Total Current Liabilities declined to $72.0 million in Q2 2026 per NRIX's latest filing, from $92.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $95.9 million in Q4 2024 and bottomed at $61.5 million in Q3 2023.
• Historically, Total Current Liabilities has averaged $78.4 million across 5 years, with a median of $78.2 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 55.12% — and 2025, when it declined 9.79%.
• Nurix Therapeutics' Total Current Liabilities stood at $70.7 million in 2022, then gained by 23.07% to $87.0 million in 2023, then grew by 10.23% to $95.9 million in 2024, then slipped by 9.79% to $86.5 million in 2025, then decreased by 16.71% to $72.0 million in 2026.
• Business Quant data shows NRIX's Total Current Liabilities at $72.0 million in Q2 2026, $92.2 million in Q1 2026, and $86.5 million in Q4 2025.